CTOs on the Move

Signature Family Wealth

www.signaturefamilywealth.com

 
Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Sonus USA

Sonus USA Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

International Biometric Group

International Biometric Group is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lila Natural Cosmetics

Lila Natural Cosmetics is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Society of Plastic Surgeons

American Society of Plastic Surgeons is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.